secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2024-07-23T23:59:59+00:00
Accession:  0001193125-24-182544
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics to present interim 4D-150 wet AMD data at September 2024 medical conference
--------------------------------------------------------------------------------

- Interim data from Phase 1/2 PRISM trial (Dose Expansion, Phase 2 Dose Expansion, Phase 2 Population Expansion cohorts) expected at September 2024 medical conference.
- Specific forum and date to be disclosed with Q2 2024 financial results in August 2024.
- 52-week landmark analyses for Dose Expansion and Population Expansion cohorts on track for February 2025 as previously disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524182544/0001193125-24-182544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524182544/d864314d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-182544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer